News | EP Lab | November 16, 2021

Acutus Medical Initiates CE Mark Study for Focal Pulsed Field Ablation Therapy for Atrial Fibrillation

AcQBlate Force will integrate multiple ablation modalities guided by noncontact mapping technology to treat complex atrial arrhythmias


November 16, 2021 — Acutus Medical Inc. (Acutus), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced the initiation of AcQForce PFA-CE, a new clinical study that will evaluate the safety and performance of the company’s focal force sensing pulsed field ablation (PFA) catheter and system in combination with its novel noncontact 3D mapping system in treating patients with atrial fibrillation. The first patients were successfully treated at Na Homolce Hospital in the Czech Republic by Dr. Petr Neuzil, the primary investigator andhead of the department of cardiology, along with his colleague Dr. Jan Petru, and Drs. Vivek Reddy and Jacob Koruth from Mount Sinai Health System. Dr. Doug Gibson of Scripps Memorial Hospital is serving as the site’s primary technology advisor.

The inception of this study highlights Acutus’ unique therapeutic position offering the first and only force sensing gold-tip ablation catheter, AcQBlate Force, designed to deliver either radiofrequency (RF) or PFA therapy—with the added benefit of fully integrating with therapy guidance provided by the novel AcQMap 3D imaging and mapping system.

“The vision for pioneering pulsed field ablation treatment was primarily due to PFA’s ability to have high-impact treatment while preserving healthy tissue. As physicians, we know that the majority of our patients that come back for re-treatment following ablation for atrial fibrillation have triggers in various locations beyond the standard course of care, and it’s imperative for us to research beyond pulmonary vein isolation-only utilizations,” said Dr. Steven Mickelsen, Acutus’ chieftranslational science officer and founder of PFA pioneer Farapulse Inc. “PFA lesion volume and contours follow well-defined and predictable electromagnetic rules, and the technology lends itself well to integration into 3D mapping systems like AcQMap. This paves the way for a higher degree of certainty and efficacy when ablating specific areas of the heart inclusive of and outside the pulmonary veins. We’re working towards a future where we can quickly create a 3D electroanatomic map of a complex arrhythmia like atrial fibrillation, and deliver precise, individualized and durable therapy with dramatically improved safety, reliability and workflow.”

“Pulsed field ablation as applied to the field of cardiac electrophysiology has enormous potential, given the expected improvements in safety, efficacy and speed over current therapies,” said Vince Burgess, president and CEO of Acutus Medical. “Our vision for the future of this new energy source is to deliver it via a force sensing focal point ablation catheter and to guide that delivery with advanced 3D cardiac mapping, rather than fluoroscopy. This approach is different from many others entering this field, in that it will allow precise applications of PFA in highly targeted tissue across the full range of arrhythmias, including atrial fibrillation and flutter and atrial and ventricular tachycardias – while preserving as much fully functional cardiac tissue as possible. Competing multi-electrode, large format catheters guided by fluoroscopy will have inherently limited precision upon delivery.”

 

Acutus’ RF Ablation System for Electrophysiology Procedures

Acutus’ therapeutic radiofrequency ablation system and force sensing catheter is currently approved and commercially available for use in Europe. It can operate in a standalone manner or in conjunction with compatible 3D mapping systems to provide consistent, effective therapy during cardiac ablation procedures. This system can also be fully integrated into Acutus’ mapping system to provide real-time displays of ablation bioparameters and contact force data.

Pulsed Field Ablation

Contemporary pulsed field ablation technologies utilize short bursts of high voltage microsecond or nanosecond electrical pulses to selectively isolate areas of cardiac tissue that are thought to contribute to triggering or sustaining cardiac arrhythmias. PFA is currently being investigated as an alternative to cryo and radiofrequency ablations, which ablate tissue by either extreme cold or extreme heat. When designed and applied appropriately, the therapeutic treatment effect of pulsed field ablation energy is almost exclusively confined to the targeted cardiac tissue without raising or lowering tissue temperature. Focal PFA may allow for more precise demarcated lesions, promoting rapid tissue healing and facilitating practical safety margins for nearby tissue structures outside the heart.

AcQForce PFA-CE Study

AcQForce PFA-CE is a prospective, non-randomized European clinical study designed to demonstrate the safety and performance of the Acutus Pulsed Field Ablation system in up to 60 patients undergoing ablation therapy for AF.

Site recruitment and patient enrollment for AcQForce PFA-CE is ongoing. For more information, please visit https://www.clinicaltrials.gov reference NCT05113056.

The AcQBlate Force Sensing System is CE marked for RF energy delivery. The AcQBlate Force Sensing System is an investigational device and is limited by United States law to investigational use. Acutus’ PFA technology is under premarket study in Europe and is not approved for sale in the U.S.

For more information: https://www.acutusmedical.com/us

 

Related Content

News | Cardiovascular Clinical Studies

June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) ...

Home June 24, 2021
Home
News | Cardiovascular Clinical Studies

January 27, 2021 — A New York Institute of Technology research team has secured a five-year $1.8 million grant from the ...

Home January 27, 2021
Home
News | Cardiovascular Clinical Studies

July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to ...

Home July 22, 2020
Home
News | Cardiovascular Clinical Studies

July 1, 2020 — Carag AG announced receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption ...

Home July 01, 2020
Home
News | Cardiovascular Clinical Studies

January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special ...

Home January 20, 2020
Home
News | Cardiovascular Clinical Studies

Environmental and lifestyle issues were popular this year, with pick up from both European Society of Cardiology (ESC) ...

Home December 23, 2019
Home
News | Cardiovascular Clinical Studies

November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have ...

Home November 26, 2019
Home
News | Cardiovascular Clinical Studies

July 10, 2019 — The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During ...

Home July 10, 2019
Home
News | Cardiovascular Clinical Studies

July 3, 2019 — The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to ...

Home July 03, 2019
Home
News | Cardiovascular Clinical Studies

November 19, 2018 — The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent ...

Home November 19, 2018
Home
Subscribe Now